CCA
DFTX

Column Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

Column Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.91K Hold
610
– – ﹤0.01% 692
2023
Q2 		$2.18K Hold
610
– – ﹤0.01% 704
2023
Q1 		$1.93K Hold
610
– – ﹤0.01% 725
2022
Q4 		$1.34K Buy
+610
New +$1.69K ﹤0.01% 735

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Column Capital Advisors's DFTX Position: Q3 2023 in Review

Column Capital Advisors held its Definium Therapeutics (DFTX) position steady in Q3 2023 at 610 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #692.

Column Capital Advisors first reported a position in DFTX in Q4 2022 and has held it in 4 quarters since. The position peaked at $2.18K in Q2 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Column Capital Advisors held 610 shares of Definium Therapeutics worth $1.91K as of Q3 2023.
  • Column Capital Advisors left its Definium Therapeutics share count unchanged in Q3 2023.
  • Definium Therapeutics made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #692 holding.
  • Column Capital Advisors first reported a position in Definium Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • Column Capital Advisors's Definium Therapeutics position peaked at $2.18K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.